The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tailored axillary surgery (TAS) in patients with clinically node-positive breast cancer in the upfront surgery setting: A prospective, single-arm, multicenter trial.
 
Kaori Terata
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichikyo; Pfizer
 
Yasuaki Sagara
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Japan; Eisai; Lilly; MSD; Pfizer
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Takehiko Sakai
No Relationships to Disclose
 
Shin Takayama
No Relationships to Disclose
 
Dai Kitagawa
No Relationships to Disclose
 
Tsuguo Iwatani
No Relationships to Disclose
 
Takahiro Tsukioki
No Relationships to Disclose
 
Mami Ogita
Honoraria - Boston Scientific
 
Naoko Sanuki
No Relationships to Disclose
 
Masayuki Yoshida
Consulting or Advisory Role - Lilly Japan; Roche
Speakers' Bureau - Agilent; Chugai Pharma; MSD; Ono Yakuhin
 
Hitoshi Tsuda
Honoraria - Daiichi Sankyo; Eisai; Kyowa Kirin; Roche
Research Funding - Chugai Pharma; Goryo Chemical; Roche
 
Seiichiro Yamamoto
No Relationships to Disclose
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)